A Phase 2, Randomized, Non-Comparative, Open-Label Study of NKTR-214 in Combination with Nivolumab and of Chemotherapy in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients with Low PD-L1 Expression

Project: Research

Project Description

NMA HREC Reference Number: HREC/52119/MonH-2019-173278(v2)
NMA SSA Reference Number: SSA/52119/MonH-2019-176919(v1)
Monash Health Ref: RES-19-0000-201A
StatusActive
Effective start/end date24/06/1923/06/24

Keywords

  • clinical trial
  • treatment efficacy
  • urothelial cancer
  • phase 2 study
  • clinical trial
  • treatment efficacy
  • urothelial cancer
  • phase 2 study
  • clinical trial
  • treatment efficacy
  • urothelial cancer
  • phase 2 study